Press releases 2013

November 25, 2013

Five-year Follow-up of Patients Treated with Radius Osteotomy and a Biphasic Absorbable Bone Substitute

November 19, 2013

18th November was EU antibiotic awareness day and the commencement of US CDC’s ‘Get Smart About Antibiotics Week’ both highlighting the Worldwide threat of antibiotic resistance

October 29, 2013

Comprehensive Summary Of Preclinical Data And Clinical Applications Of CERAMENT™|BONE VOID FILLER Published In Expert Review Of Medical Devices

October 28, 2013

Five-Year Follow-Up Data on CERAMENT™|BONE VOID FILLER Demonstrates Long-Term Safety and Long-Lasting Bone Mineral Density Improvement in Osteoporotic Patients

October 24, 2013

Great poster presentation on CERAMENT™ in foot and ankle indications, surgeon is Dr DiDomenico

October 24, 2013

BONESUPPORT™ demonstrates Corporate Social Responsibility by supporting humanitarian work in Rwanda

September 10, 2013

BONESUPPORT AB Announces the Publication of a Study Evaluating CERAMENT™|BONE VOID FILLER’s Effect on Interface Strength in a Cementless Prosthesis Animal Model

May 7, 2013

BONESUPPORT AB Returns From Medical Mission To Rwanda – CERAMENT™|G Used in the Management of Osteomyelitis

April 18, 2013

BONESUPPORT AB Plans Medical Mission To Deliver CERAMENT™|G To University Teaching Hospital Of Butare (CHUB)

April 16, 2013

BONESUPPORT™ SNNLive Video Interview with at the Sachs Forum 2013

April 12, 2013

32nd EBJIS Conference in Prague FREE PRE-WORKSHOP: Current Topics in Local Antibiotic Delivery for Osteomyelitis Management

March 27, 2013

The University of Mainz Initiates CERAMENT™| Tibia Fracture Study (CERTiFy)

March 8, 2013

BONESUPPORT Announces CE-mark And Launch Of CERAMENT™|G The First Injectable Gentamicin Eluting Bone Substitute To Promote And Protect Bone Healing In Osteomyelitis


Notes to Editor



BONESUPPORT AB has developed CERAMENT™ as an innovative range of radiopaque injectable osteoconductive bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to twelve months. Our products are effective in treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery. Our lead product, CERAMENT™|BONE VOID FILLER (BVF) addresses important issues facing health care providers, such as avoiding hospital readmissions and revision surgery that result from failed bone healing and infection caused by residual bone voids. CERAMENT|BVF is commercially available in the U.S., EU, S.E. Asia and the Middle East.

CERAMENT‘s distinctive properties as a drug eluting material have been validated in clinical practice by CERAMENT™|G and CERAMENT™ V, the first CE-marked injectable antibiotic eluting bone graft substitutes. These products provide local sustained delivery of gentamicin and vancomycin, respectively. The local delivery feature enables an initial high concentration of antibiotics to the bone defect and then a longer sustainable dose above the minimal inhibitory concentration (MIC) to protect bone healing and promote bone remodeling.

CERAMENT|G and CERAMENT™ V have demonstrated good results in patients with problematic bone infections including osteomyelitis. They are also used prophylactically in patients who are at risk for developing infection. CERAMENT|G and CERAMENT™ V are available in the EU.

BONESUPPORT AB was founded in 1999 by Prof. Lars Lidgren, an internationally respected scientist who has been the President of various musculoskeletal societies. BONESUPPORT’s mission is to bring people with bone and joint diseases back to an active life. The company is based in Lund, Sweden.

BONESUPPORT™ is a registered trademark.

Contact Information

Citigate Dewe Rogerson

David Dible, Andrea Bici, Mark Swallow

+44 (0)20 7282 2949/1050/2948